Sexually transmitted and blood‐borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder: Findings from a Canadian pragmatic randomized trial

Documents similaires

• Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder in Canada
  par: Jenna Langlois, et autres
  Publié: (2024)
• Enhancing sexually transmitted and blood‐borne infection prevention in opioid‐agonist therapy programmes: Lessons from a canadian pragmatic trial and implications for Taiwan
  par: Shu‐Chuan Chiu, et autres
  Publié: (2025)
• Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada
  par: Jenna Langlois, et autres
  Publié: (2024)
• Potentially inappropriate prescriptions and potential prescription omissions in older people living with HIV
  par: Jorge Fernández‐Fradejas, et autres
  Publié: (2024)
• Optimizing statin prescriptions for people living with HIV: Evidence for improved communication and shared care between primary care and specialist HIV services
  par: N. Li, et autres
  Publié: (2024)